Under-five mortality, with a specific focus on the prevention of pneumonia morbidity and mortality in children under-five Other
Conditions
Interventions
Current interventions as of 10/11/2020:
The intervention is a whole systems approach to building capacity, focussed on child health and paediatric pneumonia.
The intervention will delivered and eval
Sponsors
Institute for Global Health, University College London
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Resident in Kiyawa local government area, Jigawa State, Nigeria 2. A child aged 0-59 months is resident in the household
Exclusion criteria
Exclusion criteria: 1. Caregivers aged 49 years 2. Temporary residents in the study clusters 3. Individuals who decline to participate in the survey 4. Individuals who lack the capacity to consent to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome measure as of 02/03/2023: Survival time in days for children up to five years of age compared between intervention and control clusters. This will be measured as any verified deaths of eligible children, who were residing in the compound at the time of their death. Deaths will be verified by study staff during Verbal Autopsy interviews. We will exclude deaths in the first week of life due to inaccuracies in reporting of early neonatal deaths, and we do not expect the intervention to impact on perinatal causes of death. We expect very few verbal autopsies to not record dates of birth or death. For deaths missing dates in children aged 1-59 months, the WHO VA tool records an age category, and these deaths will be included, with an assumed date of death as the midpoint between the last interview where they were alive and the one where they were reported as dead. These data will be collected from self-reporting by women aged 15-49 years old during the vital events surveillance (prospective cohort evaluation), in a random sample of compounds from all villages within study clusters. Compounds will be selected using stratified random sampling within the health facility catchment areas. Primary outcome data will be collected from January 2021 to October 2022. _____ Previous primary outcome measure from 10/11/2020 to 02/03/2023: Under-five mortality compared between intervention and control clusters. This will be calculated as the number of children aged 7 days to 59 months reported to have died over a 12-month period who resided in sampled compounds (numerator), divided by the total number of children aged 7 days to 59 months who reside in sampled compounds (denominator). We will exclude deaths in the first week of life due to inaccuracies in reporting of early neonatal deaths, and we do not expect the intervention to impact on perinatal causes of death. These data will be collected from self-reporting by women aged 15-49 years old during the vit | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 10/11/2020: 1. Suspected-pneumonia under-five mortality rate, assigned using InterVA-4 2. Caregiver knowledge of pneumonia symptoms 3. Clinical pneumonia point prevalence, defined according to the World Health Organisation’s Integrated Management of Childhood Illnesses guidelines 4. Care-seeking behaviours for pneumonia 5. Vaccination coverage 6. Protective/prevention measures for pneumonia including exclusive breastfeeding, handwashing with soap, no indoor smoke from cooking. These data will be collected from women aged 15-49 years old during compound surveys and from clinical screening of children under-five by a study nurse, in a random sample of compounds from all villages within study clusters. Compounds will be selected using stratified random sampling within the health facility catchment areas. The trial will run from January 2021 to October 2022. Two cross-sectional surveys will be conducted (01/21-03/21 baseline survey, 07/22-09/22 – endline survey), and prospective recording of vital events will be done every four months in between the baseline and endline survey. _____ Previous secondary outcome measures: 1. Suspected-pneumonia under-five mortality rate 2. Caregiver knowledge of pneumonia symptoms 3. Clinical pneumonia point prevalence 4. Care-seeking behaviours for pneumonia 5. Vaccination coverage These data will be collected from women aged 15-49 years old during household surveys and from clinical screening of children under-five by a study nurse, in a random sample of households from all villages within study clusters. Households will be selected using stratified random sampling. Data will be collected at three timepoints, a baseline survey (January-March 2020), midline survey (January-March 2021) and endline survey (January-March 2022). | — |
Countries
Nigeria
Outcome results
None listed